Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG0259 in Active Rheumatoid Arthritis
NCT01211249Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of GLPG-0259 in rheumatoid arthritis (RA) (4 arms), sponsored by Galapagos NV. Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started Oct 2010; status: completed.
02
Drugs
GLPG-0259
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01211249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211249.